Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G
Digestive Cancer Registry of Calvados, Cancers and Populations, National Institute of Health and Medical Research (ESPRI), Caen, France.
Br J Surg. 2006 Apr;93(4):465-74. doi: 10.1002/bjs.5278.
The aim of this population-based study was to evaluate the incidence, management and prognosis of patients with hepatic metastases related to colorectal cancer using data from the Digestive Cancer Registry of Calvados, France.
Of 1325 patients with colorectal cancer registered between January 1994 and December 1999, 358 developed hepatic metastases. Logistic regression was used to analyse prognostic factors. Survival analysis was carried out with Cox's proportional hazards model.
Some 18.8 per cent of patients had synchronous metastases, while 29.3 per cent developed metastases at 3 years. Of patients with hepatic metastases, 17.3 per cent had a surgical resection, 40.2 per cent were treated with palliative chemotherapy and 42.5 per cent had symptomatic treatment. Factors associated with receiving symptomatic treatment only were age over 75 years and more than one metastasis, but not place of treatment. Median survival after a diagnosis of hepatic metastases was 10.7 (range 4.6-23.1) months. Significant adverse prognostic factors were: age over 75 years (P = 0.001), lymph node invasion of primary tumour (P = 0.024), bilateral distribution of metastases (P = 0.001), other metastases (P = 0.004) and symptomatic treatment only (P = 0.041).
Despite improvement in treatment for hepatic metastases, age and extent of disease remain limiting factors for surgical resection and palliative chemotherapy.
本基于人群的研究旨在利用法国卡尔瓦多斯消化癌登记处的数据,评估结直肠癌肝转移患者的发病率、治疗及预后情况。
1994年1月至1999年12月登记的1325例结直肠癌患者中,358例发生了肝转移。采用逻辑回归分析预后因素。使用Cox比例风险模型进行生存分析。
约18.8%的患者发生同步转移,29.3%的患者在3年内发生转移。肝转移患者中,17.3%接受了手术切除,40.2%接受了姑息化疗,42.5%接受了对症治疗。仅接受对症治疗相关的因素为年龄超过75岁和转移灶多于一处,但与治疗地点无关。肝转移诊断后的中位生存期为10.7(范围4.6 - 23.1)个月。显著的不良预后因素为:年龄超过75岁(P = 0.001)、原发肿瘤的淋巴结侵犯(P = 0.024)、转移灶的双侧分布(P = 0.001)、其他转移(P = 0.004)以及仅接受对症治疗(P = 0.041)。
尽管肝转移的治疗有所改善,但年龄和疾病范围仍然是手术切除和姑息化疗的限制因素。